|
1,107
|
| 7243 |
APOE (isoform E4)
|
|
increases_activity of
|
Alzheimer disease
|
|
| 7344 |
APOE (isoform E4)
|
|
increases_quantity of
|
amyloid beta deposits
|
|
|
20462385
|
|
1,441
|
| 10320 |
APOE (isoform E4)
|
|
increases_activity of
|
Alzheimer disease
|
|
|
19166904
|
|
1,893
|
| 14500 |
APOE (isoform E4)
|
|
increases_activity of
|
Alzheimer disease
|
|
| 14502 |
APOE (isoform E4)
|
|
increases_activity of
|
neurodegeneration
|
|
| 14513 |
APOE (isoform E4)
|
|
increases_activity of
|
Parkinson disease
|
|
| 14514 |
APOE (isoform E4)
|
|
increases_activity of
|
Multiple sclerosis
|
|
| 14519 |
APOE (isoform E4)
|
|
affects_activity of
|
synapse assembly
|
|
| 14521 |
APOE (isoform E4)
|
|
decreases_activity of
|
learning or memory
|
compared to apo E3 knock-in mice
|
| 14529 |
APOE (isoform E4)
|
|
increases_quantity of
|
amyloid beta deposits
|
|
| 14558 |
APOE (isoform E4)
|
|
interacts (colocalizes) with
|
ABCA1
|
|
|
20170744
|
|
1,957
|
| 15166 |
APOE (isoform E4)
|
|
decreases_activity of
|
metabolic process
|
progressive in late-middle-aged persons
|
|
19076444
|
|
2,072
|
| 16715 |
APOE (isoform E4)
|
|
increases_activity of
|
decreased brain blood flow rate
|
in ApoE4 6-month and 12-month mice; compared to WT mouse
|
| 16716 |
APOE (isoform E4)
|
|
increases_activity of
|
decreased cerebral blood flow rate
|
in ApoE4 6-month and 12-month mice; compared to WT mouse
|
| 16717 |
APOE (isoform E4)
|
|
increases_activity of
|
brain hypoperfusion
|
in ApoE4 6-month and 12-month mice; compared to WT mouse
|
| 16719 |
APOE (isoform E4)
|
|
increases_activity of
|
Alzheimer disease
|
in APOE4 mice
|
| 16751 |
APOE (isoform E4)
|
|
increases_activity of
|
response to stress
|
in APOE4 mouse microvessels
|
| 16752 |
APOE (isoform E4)
|
|
affects_activity of
|
vascular endothelium
|
in APOE4 mouse microvessels
|
| 38965 |
APOE (isoform E4)
|
|
decreases_activity of
|
learning or memory
|
in APOE4 mice; if mice are fed with selective mitochondrial antioxidants acetyl-L-carnitine and R-alpha-lipoic acid
|
| 95893 |
APOE (isoform E4)
|
|
increases_activity of
|
cognitive impairment
|
in APOE4 mice; improved cognitive impairment if mice are fed with selective mitochondrial antioxidants acetyl-L-carnitine and R-alpha-lipoic acid
|
| 95894 |
mitochondrial antioxidant
|
|
decreases_activity of
|
APOE (isoform E4)
|
in APOE4 mice; improved cognitive impairment if mice are fed with selective mitochondrial antioxidants acetyl-L-carnitine and R-alpha-lipoic acid
|
| 95895 |
Acetylcarnitine
|
|
decreases_activity of
|
APOE (isoform E4)
|
in APOE4 mice; improved cognitive impairment if mice are fed with selective mitochondrial antioxidants acetyl-L-carnitine and R-alpha-lipoic acid
|
| 95896 |
R-alpha-lipoic acid
|
|
decreases_activity of
|
APOE (isoform E4)
|
in APOE4 mice; improved cognitive impairment if mice are fed with selective mitochondrial antioxidants acetyl-L-carnitine and R-alpha-lipoic acid
|
|
19342064
|
|
2,533
|
| 23594 |
APOE (isoform E4)
|
|
increases_activity of
|
Alzheimer disease
|
|
|
21448224
|
|
3,081
|
| 28303 |
APOE (isoform E4)
|
|
affects_activity of
|
Amyloid beta peptide (40)
|
|
| 28308 |
Amyloid beta peptide (12-28)
|
|
interacts (colocalizes) with
|
APOE (isoform E4)
|
|
| 28341 |
APOE (isoform E4)
|
|
increases_activity of
|
response to nitrosative stress
|
|
|
22101739
|
|
3,167
|
| 29109 |
APOE (isoform E4)
|
|
increases_quantity of
|
amyloid beta deposits
|
|
|
20598287
|
|
3,191
|
| 118869 |
APOE (isoform E4)
|
|
increases_expression of
|
CASP6
|
in the temporal cortex of the APOE4 group; strongly upregulated
|
| 118870 |
APOE (isoform E4)
|
|
decreases_expression of
|
CASP6
|
in the primary somatosensory cortex of the APOE4 group; modestely downregulated
|
|
20479757
|
|
3,699
|
| 35842 |
APOE (isoform E4)
|
|
increases_activity of
|
Alzheimer disease
|
In the presence of type 2 DM the risk of developing AD is increased to more than five-fold, compared to individuals without those two conditions.
|
|
22329649
|
|
6,481
|
| 62475 |
APOE (isoform E4)
|
|
increases_activity of
|
leptin-mediated signaling pathway
|
Accumulation of ApoE4 results in a transient enhancement of Lep signalling that might lead to Lep resistance over time.
|
| 62483 |
APOE (isoform E4)
|
|
increases_activity of
|
inflammatory response
|
|
| 62516 |
APOE (isoform E4)
|
|
increases_activity of
|
gliosis
|
in the brain; in transgenic animal models overexpressing human form of apoE4 .
|
|
25998028
|
|
7,238
|
| 71247 |
APOE (isoform E4)
|
|
decreases_activity of
|
Alzheimer disease
|
in plasma; among women, in the Baltimore Longitudinal Study of Aging;
|
| 71259 |
sex
|
|
affects_activity of
|
APOE (isoform E4)
|
in plasma; concerning the risk of AD in the Baltimore Longitudinal Study of Aging;
|
| 71262 |
APOE (isoform E4)
|
NOT |
affects_activity of
|
Ceramide
|
in plasma ; concerning the risk of AD among men and women in the Baltimore Longitudinal Study of Aging;
|
| 71264 |
APOE (isoform E4)
|
NOT |
affects_activity of
|
Sphingomyelin
|
in plasma; concerning the risk of AD among men in the Baltimore Longitudinal Study of Aging;
|
|
|
|
7,250
|
| 71302 |
APOE (isoform E4)
|
|
increases_expression of
|
APP
|
in human neurons; compared to ApoE3 and ApoE2
|
| 71312 |
APOE (isoform E4)
|
|
increases_activity of
|
Abeta (42) secretion
|
in human neurons cultured on MEFs ; compared to ApoE3 and ApoE2
|
| 71315 |
APOE (isoform E4)
|
|
increases_activity of
|
Abeta (40) secretion
|
in human neurons cultured on MEFs ; compared to ApoE3 and ApoE2
|
| 71334 |
APOE (isoform E4)
|
|
increases_activity of
|
MAP3K12
|
in human neurons; compared to ApoE3 and ApoE2;
via binding to ApoE receptors
|
| 71364 |
APOE (isoform E4)
|
|
increases_activity of
|
Alzheimer disease
|
if human neurons are cultured on mouse glia;
|
| 124911 |
APOE (isoform E4)
|
|
increases_quantity of
|
Amyloid beta peptide (42)
|
compared to ApoE3 and ApoeE2; unrelated to alpha-or beta-secretase expression
|
| 124917 |
APOE (isoform E4)
|
|
increases_quantity of
|
Amyloid beta peptide (40)
|
compared to ApoE3 and ApoeE2; unrelated to alpha-or beta-secretase expression
|
|
28111074
|
|
7,255
|
| 71375 |
APOE (isoform E4)
|
|
increases_activity of
|
abnormal circulating lipid level
|
|
| 71388 |
APOE (isoform E4)
|
|
affects_activity of
|
low-density lipoprotein particle receptor binding
|
Binding of APOE4 to the LDLR is unaffected
|
| 71391 |
APOE (isoform E4)
|
|
increases_activity of
|
lipid binding
|
The amino acid substitution affects the organization and stability of both the N-terminal helix bundle domain and separately folded C-terminal domain so that apoE4 has enhanced lipid binding ability.
|
| 71392 |
APOE (isoform E4)
|
|
increases_activity of
|
very-low-density lipoprotein particle binding
|
The strong lipid binding ability of apoE4 is the basis for the preferential binding of this isoform to VLDL particles, the surfaces of which are about 60% PL-covered. ApoE4 binds much better than apoE3 to VLDL but somewhat less well than apoE3 to HDL.
|
| 71394 |
APOE (isoform E4)
|
|
increases_activity of
|
alatered VLDL lipolytic processing
|
ApoE4 binds better than apoE3 to the surface of very low density lipoprotein (VLDL) particles and impairs their lipolytic processing in the circulation.
|
| 71403 |
APOE (isoform E4)
|
|
increases_activity of
|
increased pro-atherogenic lipoprotein-cholesterol distribution
|
|
| 71423 |
APOE (isoform E4)
|
|
increases_activity of
|
increased circulating VLDL cholesterol level
|
in transgenic mouse, in plasma
|
| 71430 |
APOE (isoform E4)
|
|
increases_activity of
|
increased susceptibility to atherosclerosis
|
in transgenic mouse, in plasma
|
| 71431 |
APOE (isoform E4)
|
|
increases_activity of
|
increased circulating cholesterol level
|
|
| 71436 |
APOE (isoform E4)
|
|
decreases_activity of
|
high-density lipoprotein particle binding
|
compared to apoE3;
ApoE4 binds much better than apoE3 to VLDL but somewhat less well than apoE3 to HDL
|
| 71448 |
APOE (isoform E4)
|
|
decreases_activity of
|
lipid catabolic process
|
ApoE4 binds more to VLDL because of its higher lipid affinity leading to inhibition of lipolysis
|
| 111429 |
APOE (isoform E4)
|
|
interacts (colocalizes) with
|
VLDL
|
ApoE4 binds more to VLDL because of its higher lipid affinity leading to inhibition of lipolysis
|
| 113458 |
APOE (isoform E4)
|
|
decreases_activity of
|
cholesterol homeostasis
|
resulting in Hypercholesterolemia
|
| 114524 |
APOE (isoform E4)
|
|
decreases_activity of
|
VLDL lipid catabolic process
|
ApoE4 binds more to VLDL because of its higher lipid affinity leading to inhibition of lipolysis
|
|
25328986
|
|
7,288
|
| 71590 |
APOE (isoform E4)
|
|
increases_quantity of
|
APOB
|
with no gender effect
|
| 73921 |
APOE (isoform E4)
|
|
increases_activity of
|
Alzheimer disease
|
only below age 80
|
| 73922 |
aging
|
|
increases_activity of
|
APOE (isoform E4)
|
only below age 80
|
| 73923 |
APOE (isoform E4)
|
|
increases_quantity of
|
Cholesterol
|
in men
|
|
11408727
|
|
7,308
|
| 71708 |
APOE (isoform E4)
|
|
increases_activity of
|
Alzheimer disease
|
|
| 71716 |
APOE (isoform E4)
|
|
decreases_activity of
|
S1P/sphingosine ratio
|
in hippocampus
|
|
24456642
|
|
7,322
|
| 71967 |
APOE (isoform E4)
|
|
increases_activity of
|
Alzheimer disease
|
|
| 71968 |
sex, female
|
|
increases_activity of
|
APOE (isoform E4)
|
concerning AD in females / women
|
| 71969 |
APOE (isoform E4)
|
|
decreases_activity of
|
hippocampus
|
depending on sex: worse in females / women compared to males /men at different stages of AD.
|
| 71970 |
APOE (isoform E4)
|
|
affects_activity of
|
brain
|
|
| 71971 |
APOE (isoform E4)
|
|
decreases_activity of
|
memory
|
depending on sex: worse in females / women compared to males / men at different stages of AD.
|
| 71972 |
APOE (isoform E4)
|
|
increases_quantity of
|
amyloid beta deposits
|
especially in APOE4 females / women
|
| 71973 |
APOE (isoform E4)
|
|
increases_quantity of
|
neurofibrillary tangles
|
especially in APOE4 females / women
|
| 72092 |
APOE (isoform E4)
|
|
increases_activity of
|
Alzheimer disease
|
concerning AD in females / women
|
| 124712 |
sex, male
|
|
decreases_activity of
|
APOE (isoform E4)
|
in males / men; concerning AD, compared to females / women
|
|
24470773
|
|
7,412
|
| 72681 |
APOE (isoform E4)
|
|
increases_activity of
|
Alzheimer disease
|
|
|
26969397
|
|
7,515
|
| 74144 |
APOE (isoform E4)
|
|
decreases_quantity of
|
APOE
|
in plasma; in a group of APOE4 alelle carrier from Australia
|
| 74145 |
APOE (isoform E4)
|
|
decreases_quantity of
|
APOC3
|
in plasma; in a group of APOE4 alelle carrier from Australia
|
| 74146 |
APOE (isoform E4)
|
|
decreases_quantity of
|
APOH
|
in plasma; in a group of APOE4 alelle carrier from Australia
|
| 74147 |
APOE (isoform E4)
|
|
increases_quantity of
|
APOB
|
in plasma; in a group of APOE4 alelle carrier from Australia
|
|
22701550
|
|
7,522
|
| 74174 |
APOE (isoform E4)
|
|
decreases_activity of
|
spartial memory
|
in APOA4 female mice
|
| 74176 |
APOE (isoform E4)
|
|
decreases_activity of
|
memory
|
in APOA4 female mice
|
| 74185 |
APOE (isoform E4)
|
|
decreases_activity of
|
AR
|
|
| 74190 |
APOE (isoform E4)
|
|
interacts (colocalizes) with
|
AR
|
in cortical extracts; in Apo-/- mice
|
| 74196 |
APOE (isoform E4)
|
|
decreases_quantity of
|
AR-positive neurons
|
in female
|
| 74197 |
APOE (isoform E4)
|
NOT |
affects_quantity of
|
AR-positive neurons
|
in male
|
|
18395206
|
|
7,773
|
| 77653 |
APOE (isoform E4)
|
|
increases_quantity of
|
Cholesterol
|
in plasma
|
|
28697566
|
|
7,815
|
| 77782 |
APOE (isoform E4)
|
|
increases_quantity of
|
Ceramide C20-C26
|
in CSF in CN with a parental history of AD
|
|
24952994
|
|
7,848
|
| 78037 |
APOE (isoform E4)
|
|
increases_activity of
|
Alzheimer disease
|
|
| 78301 |
APOE (isoform E4)
|
|
decreases_activity of
|
sterol metabolic process
|
in AD but not normal brain
|
| 78302 |
APOE (isoform E4)
|
|
decreases_activity of
|
sphingolipid metabolic process
|
in AD but not normal brain
|
| 78329 |
APOE (isoform E4)
|
|
increases_quantity of
|
Cholesterol
|
in the MFG (middle frontal gyrus) grey matter of AD patients (in the cell bodies but not in the fiber tracks); compared with AD patients expressing ApoE3
|
| 78335 |
APOE (isoform E4)
|
|
decreases_quantity of
|
SM C22:0
|
in the MFG grey matter in ApoE4 compared with ApoE3 AD brain; (12.5-fold decrease)
|
| 78337 |
APOE (isoform E4)
|
|
increases_quantity of
|
Ceramide C22:0
|
in the MFG white matter in ApoE4 vs. ApoE3 brain; (2.6-fold increase)
|
| 78338 |
APOE (isoform E4)
|
|
increases_quantity of
|
4-Hydroxynonenal
|
in the MFG grey matter of ApoE4 compared with ApoE3 AD brain; (4.9-fold increase)
|
| 78339 |
APOE (isoform E4)
|
|
increases_quantity of
|
Ceramide C18:0
|
in the MFG grey matter of ApoE4 AD patients
|
| 78369 |
APOE (isoform E4)
|
|
increases_quantity of
|
Cholesterol ester C18:1
|
in the MTG (middle temporal gyrus) grey matter in AD patients expressing ApoE4, (in the cell bodies but not in the fiber tracks); (2.4-fold increase), compared with AD patients expressing ApoE3
|
| 78370 |
APOE (isoform E4)
|
|
increases_quantity of
|
Cholesterol ester C16:0
|
in the MFG (middle frontal gyrus) grey matter of AD patients (in the cell bodies but not in the fiber tracks); compared with AD patients expressing ApoE3
|
| 78371 |
APOE (isoform E4)
|
|
increases_quantity of
|
Cholesterol ester C18:1
|
in the MFG (middle frontal gyrus) grey matter of AD patients (in the cell bodies but not in the fiber tracks); compared with AD patients expressing ApoE3
|
| 78372 |
APOE (isoform E4)
|
|
decreases_quantity of
|
SM C24:0
|
in the MFG grey matter in ApoE4 compared with ApoE3 AD brain; (6.2-fold decrease)
|
| 78373 |
APOE (isoform E4)
|
|
decreases_quantity of
|
Ceramide C24:0
|
in the MFG white matter in ApoE4 vs. ApoE3 brain; (1.2-fold decrease)
|
| 78374 |
APOE (isoform E4)
|
|
increases_quantity of
|
Sulfatide
|
in the MFG white matter in ApoE4 vs. ApoE3 brain; (1.7-fold increase)
|
| 78377 |
APOE (isoform E4)
|
|
increases_quantity of
|
Ceramide C24:1
|
in the MFG grey matter of ApoE4 AD patients
|
| 78378 |
APOE (isoform E4)
|
|
increases_quantity of
|
Sulfatide
|
in the MFG grey matter of ApoE4 AD patients
|
|
17888544
|
|
7,868
|
| 78405 |
APOE (isoform E4)
|
|
increases_quantity of
|
Amyloid beta peptide (42, insoluble)
|
extracellular, in the hippocampus and cortex of ovariectomized female EFAD mice, treated for 3 months with 17- estradiol
|
| 102069 |
APOE (isoform E4)
|
|
affects_activity of
|
Estradiol
|
in ovariectomized EFAD mice treated with estradiol; extracellular amyloid plaque and Abeta deposition is increased with APOE4
|
| 102070 |
APOE (isoform E4)
|
|
increases_quantity of
|
Amyloid beta peptide (total levels)
|
in ovariectomized EFAD mice treated with estradiol
|
| 102071 |
APOE (isoform E4)
|
|
decreases_quantity of
|
Amyloid beta peptide (soluble)
|
in ovariectomized EFAD mice treated with estradiol
|
|
24368217
|
|
7,871
|
| 78388 |
APOE (isoform E4)
|
|
decreases_activity of
|
amyloid-beta clearance
|
via lower levels of hippocampal insulin degrading enzyme
|
| 79062 |
APOE (isoform E4)
|
|
decreases_quantity of
|
IDE
|
in hippocampus
|
|
26708713
|
|
7,977
|
| 104426 |
APOE (isoform E4)
|
|
increases_quantity of
|
APOE (lipid-depleted)
|
in cerebrospinal fluid of adults
|
|
23779114
|
|
8,026
|
| 84824 |
APOE (isoform E4)
|
|
increases_activity of
|
Estradiol
|
in recently postmenopausal women; concerning Transdermal 17beta-estradiol therapy; particularly in APOE4 carriers
|
|
27163830
|
|
8,063
|
| 79910 |
APOE (isoform E4)
|
|
decreases_quantity of
|
N-Acylsphingosine C16:0
|
in human ApoE4 female mouse brain; compared to WT mice
|
| 79914 |
APOE (isoform E4)
|
|
decreases_quantity of
|
N-Acylsphingosine C24:1
|
in human ApoE4 female mouse brain; compared to WT mice
|
| 79918 |
APOE (isoform E4)
|
|
decreases_quantity of
|
Saturated fatty acid
|
in human ApoE4 female mouse; compared to ApoE-knockout (E0) mice
|
| 79922 |
APOE (isoform E4)
|
|
decreases_quantity of
|
Fatty acid
|
in human ApoE4 female mouse; compared to ApoE-knockout (E0) mice
|
| 79934 |
APOE (isoform E4)
|
|
decreases_expression of
|
CERS6
|
in chow-fed human ApoE4 female mouse; compared to both WT and ApoE-knockout (E0) mice, concerning mRNA CERS6 level
|
| 79938 |
APOE (isoform E4)
|
|
decreases_expression of
|
SMPD1
|
in chow-fed human ApoE4 female mouse; compared to both WT and ApoE-knockout (E0) mice, concerning mRNA level
|
| 79940 |
APOE (isoform E4)
|
|
decreases_expression of
|
Ceramide transporter
|
in chow-fed human ApoE4 female mouse; compared to both WT and ApoE-knockout (E0) mice, concerning mRNA level
|
| 79941 |
APOE (isoform E4)
|
|
decreases_expression of
|
Fatty acid transporter
|
in chow-fed human ApoE4 female mouse; compared to both WT and ApoE-knockout (E0) mice, concerning mRNA level
|
|
28035926
|
|
8,119
|
| 82232 |
APOE (isoform E4)
|
|
increases_activity of
|
amyloid fibril formation
|
in mice expressing human ApoE4; compared with other ApoE isoforms
|
|
15084661
|
|
8,196
|
| 82376 |
APOE (isoform E4)
|
|
increases_activity of
|
Alzheimer disease
|
concerning the age (younger age at onset)
|
|
|
AlzNet-DB